Salvage fractionated stereotactic radiotherapy with or without chemotherapy and immunotherapy for recurrent glioblastoma multiforme: A single institution experience

Frontiers in Oncology

Volumn 5, Issue MAY, 2015, Pages

  Hasan, Shaakir ^a   Chen, Eda ^a   Lanciano, Rachelle ^a,b   Yang, Jun ^a,b   Hanlon, Alex ^a,c   Lamond, John ^a,b   Arrigo, Stephen ^a,b   Ding, William ^a,b   Mikhail, Michael ^a   Ghaneie, Arezoo ^a   Brady, Luther ^a,b  

^a Philadelphia CyberKnife Crozer Keystone Healthcare System   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Glioblastoma multiforme; Glioblastoma radiosurgery; Glioblastoma stereotactic; Recurrent glioblastoma; Salvage stereotactic

Indexed keywords

BEVACIZUMAB; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYBERKNIFE; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; IMMUNOTHERAPY; KARNOFSKY PERFORMANCE STATUS; MALE; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; SALVAGE FRACTIONATED STEREOTACTIC RADIOTHERAPY; SALVAGE THERAPY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME;

EID: 84934280973     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00106     Document Type: Article

References (51)

1. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys (1989) 16:1405-9. doi:10.1016/0360-3016(89)90941-3
2. Barker FG II, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery (1998) 42:709-20. doi:10.1097/00006123-199804000-00013 discussion 720-703
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352:987-96. doi:10.1056/NEJMoa043330
4. Romanelli P, Conti A, Pontoriero A, Ricciardi GK, Tomasello F, De Renzis C, et al. Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme. Neurosurg Focus (2009) 27:E8. doi:10.3171/2009.9.FOCUS09187
5. Barbagallo GM, Jenkinson MD, Brodbelt AR. 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg (2008) 22:452-5. doi:10.1080/02688690802182256
6. Brandes AA, Bartolotti M, Franceschi E. Second surgery for recurrent glioblastoma: advantages and pitfalls. Expert Rev Anticancer Ther (2013) 13:583-7. doi:10.1586/era.13.32
7. Brandes AA, Vastola F, Monfardini S. Reoperation in recurrent high-grade gliomas: literature review of prognostic factors and outcome. Am J Clin Oncol (1999) 22:387-90. doi:10.1097/00000421-199908000-00013
8. Brandes AA, Pasetto LM, Monfardini S. New drugs in recurrent high grade gliomas. Anticancer Res (2000) 20:1913-20. doi:10.1159/000012158
9. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet (1995) 345:1008-12. doi:10.1016/S0140-6736(95)90755-6
10. Chamberlain MC, Tsao-Wei DD. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer (2004) 100:1213-20. doi:10.1002/cncr.20072
11. Chua SL, Rosenthal MA, Wong SS, Ashley DM, Woods AM, Dowling A, et al. Phase 2 study of temozolomide and caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol (2004) 6:38-43. doi:10.1215/S1152851703000188
12. Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traish D, et al. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer (1994) 30A:1809-15. doi:10.1016/0959-8049(94)00248-4
13. Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol (2008) 26:1012-3. doi:10.1200/JCO.2007.15.1605
14. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2009) 27:740-5. doi:10.1200/JCO.2008.16.3055
15. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2010) 12:95-103. doi:10.1093/neuonc/nop015
16. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 25:4722-9. doi:10.1200/jco.2007.12.2440
17. Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol (2010) 21:1723-7. doi:10.1093/annonc/mdp591
18. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE II, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol (2010) 96:219-30. doi:10.1007/s11060-009-9950-0
19. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol (2010) 12:1300-10. doi:10.1093/neuonc/noq099
20. Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg (2010) 113:192-8. doi:10.3171/2010.2.JNS091211
21. Amelio D, Amichetti M. Radiation therapy for the treatment of recurrent glioblastoma: an overview. Cancers (Basel) (2012) 4:257-80. doi:10.3390/cancers4010257
22. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery (2002) 51:343-55. doi:10.1097/00006123-200208000-00009 discussion 355-347
23. Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys (1998) 41:1005-11. doi:10.1016/S0360-3016(98)00159-X
24. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys (2004) 60:853-60. doi:10.1016/j.ijrobp.2004.04.011
25. Lanciano R, Lamond J, Yang J, Feng J, Arrigo S, Good M, et al. Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol (2012) 2:23. doi:10.3389/fonc.2012.00023
26. Hall WA, Djalilian HR, Sperduto PW, Cho KH, Gerbi BJ, Gibbons JP, et al. Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol (1995) 13:1642-8.
27. Shrieve DC, Alexander E III, Wen PY, Fine HA, Kooy HM, Black PM, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery (1995) 36:275-82. doi:10.1097/00006123-199502000-00006 discussion 282-274
28. Larson DA, Prados M, Lamborn KR, Smith V, Sneed PK, Chang S, et al. Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys (2002) 54:1397-404. doi:10.1016/S0360-3016(02)03743-4
29. Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery (1997) 41:776-83. doi:10.1097/00006123-199710000-00004 discussion 783-775
30. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer (2005) 104:2168-73. doi:10.1002/cncr.21429
31. Mahajan A, McCutcheon IE, Suki D, Chang EL, Hassenbusch SJ, Weinberg JS, et al. Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J Neurosurg (2005) 103:210-7. doi:10.3171/jns.2005.103.2.0210
32. Hsieh PC, Chandler JP, Bhangoo S, Panagiotopoulos K, Kalapurakal JA, Marymont MH, et al. Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme. Neurosurgery (2005) 57:684-92. doi:10.1227/01.NEU.0000175550.96901.A3 discussion 684-692
33. Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys (1999) 45:1133-41. doi:10.1016/S0360-3016(99)00336-3
34. Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol (2009) 92:185-91. doi:10.1007/s11060-008-9752-9
35. Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys (1999) 43:293-8. doi:10.1016/S0360-3016(98)00416-7
36. Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer (2005) 5:55. doi:10.1186/1471-2407-5-55
37. Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E, et al. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol (2000) 23:155-9. doi:10.1097/00000421-200004000-00010
38. Pouratian N, Crowley RW, Sherman JH, Jagannathan J, Sheehan JP. Gamma knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma. J Neurooncol (2009) 94:409-18. doi:10.1007/s11060-009-9873-9
39. Greenspoon JN, Sharieff W, Hirte H, Overholt A, Devillers R, Gunnarsson T, et al. Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study. Onco Targets Ther (2014) 7:485-90. doi:10.2147/OTT.S60358
40. Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery (1987) 21:607-14. doi:10.1097/00006123-198711000-00001
41. Landy HJ, Feun L, Schwade JG, Snodgrass S, Lu Y, Gutman F. Retreatment of intracranial gliomas. South Med J (1994) 87:211-4. doi:10.1097/00007611-199402000-00013
42. Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol (1999) 52:371-9. doi:10.1016/S0090-3019(99)00103-2
43. Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir (2001) 62:43-7. doi:10.1055/s-2002-19477
44. Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol (2008) 69:506-9. doi:10.1016/j.surneu.2007.03.043 discussion 509
45. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 28:3838-43. doi:10.1200/JCO.2010.30.0582
46. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 13:1118-24. doi:10.1093/neuonc/nor110
47. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol (2007) 25:2601-6. doi:10.1200/JCO.2006.08.1661
48. Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer (2012) 48:1176-84. doi:10.1016/j.ejca.2012.02.004
49. Kong DS, Lee JI, Park K, Kim JH, Lim DH, Nam DH. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer (2008) 112:2046-51. doi:10.1002/cncr.23402
50. Yazici G, Cengiz M, Ozyigit G, Eren G, Yildiz F, Akyol F, et al. Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol (2014) 120(1):117-23. doi:10.1007/s11060-014-1524-0
51. Martínez-Carrillo M, Tovar-Martín I, Zurita-Herrera M, Del Moral-Ávila R, Guerrero-Tejada R, Saura-Rojas E, et al. Salvage radiosurgery for selected patients with recurrent malignant gliomas. Biomed Res Int (2014) 2014:657953. doi:10.1155/2014/657953